Once-Daily Evening Administration of Uniphyl Tablets: Announcement of First Available Chronotherapy of Nocturnal Asthma

Abstract

Theophylline chronotherapy recently became a reality for patients with reversible airways disease. Uniphyl^R 400 mg tablets (controlled-release theophylline, the Purdue Frederick Company, Norwalk, Connecticut) are now indicated for once-daily evening administration, both in the United States and Canada. This development follows the previous use of Uniphyl tablets in once-daily morning doses and marks the first-available antiasthmatic treatment in North America to incorporate dosing time as an important therapeutic dimension. It reflects increasing recognition, by the medical community, of the need to consider the individual patient's timing of symptoms in relation to the kinetics of the drug.